Clinical Trial Update: A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of Onartuzumab alone or in combination with Sorafenib in participants with advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Onartuzumab (onartuzumab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: COMPLETED